(PDF) Comparison of Branded and Generic Imatinib Plasma

Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study

Clinical Lymphoma, Myeloma and Leukemia - United States

doi 10.1016/j.clml.2016.04.003

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

August 1, 2016

Authors

Dubravka Sertic

Sandra Basic-Kinda

Ranka Serventi-Seiwerth

Publisher

Elsevier BV

Related search

Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia

English

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Clinical Journal of Oncology Nursing

English

Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Clinical Cancer Research

Cancer Research

English

The Clinical Relevance of Imatinib Plasma Trough Concentrations in Chronic Myeloid Leukemia. A Belgian Study

Clinical Biochemistry

Clinical Biochemistry

English

Treatment of Chronic Myeloid Leukemia With Generic Imatinib in Patients From Northeastern Part of India

International Journal of Research in Pharmaceutical Sciences

English

Imatinib Mesylate Suppresses Cytokine Synthesis by Activated CD4 T Cells of Patients With Chronic Myelogenous Leukemia

Cancer Research

English

An Analysis of Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia With Imatinib-Resistant Mutations

Mathematical Biosciences

Molecular Biology

Applied Mathematics

Biological Sciences

English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research

Cancer Research

English

Chronic Myelogenous Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN

English